• City View Green (CVGR) announced a non-brokered private placement for proceeds of up to $1,000,000
  • The company will issue up to 66,666,667 common shares at a price of $0.015 per share
  • The company has closed the first tranche of the offering, raising gross proceeds of $325,000
  • City View is a CPG company focused on the development of cannabis-infused edibles
  • City View Green Holdings Inc. (CVGR) opened trading at C$0.005

City View Green (CVGR) announced a non-brokered private placement for proceeds of up to $1,000,000.

The company will issue up to 66,666,667 common shares at a price of $0.015 per share.

Proceeds will be used for general working capital.

The company has closed the first tranche of the offering, issuing 21,666,668 shares for gross proceeds of $325,000.

Rob Fia, the company’s President, CEO and director, purchased 3,333,334 shares for $50,000 under the first tranche.

City View is a consumer packaged goods company focused on the development of cannabis-infused edibles. City View will incorporate cannabis-infused food production at its Brantford, Ontario facility. City View owns a 27.5 per cent stake in Budd Hutt Inc., a retail-focused cannabis company with access to cannabis cultivation and production licenses in Alberta and other retail opportunities across Canada.

City View Green Holdings Inc. (CVGR) opened trading at C$0.005.


More From The Market Online
Docebo Inc. - CEO, Claudio Erba

Docebo stock rallies on 2023 financial report

Software firm Docebo (TSX:DCBO) reported its Q4 and fiscal year 2023 financial results above analysts’ estimates.

FaZe Clan stockholders approve GameSquare merger

FaZe Holdings Inc. (NASDAQ:FAZE) announced that its stockholders have voted to approve the proposed merger with GameSquare (NASDAQ:GAME).

Zonte Metals discovers large copper-in-soil anomalies in Newfoundland

Zonte Metals (TSXV:ZON) has discovered copper-in-soil anomalies at its Cross Hills Copper Project in Newfoundland.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.